Incyte drug combination reduces lymphoma progression risk by 25%
Go back to Incyte drug combination reduces lymphoma progression risk by 25%| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 105.39 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $105.39 | 52 Week High | $118.49 | |||
| Open | $105.39 | 52 Week Low | $55.00 | |||
| Day High | $105.39 | P/E | N/A | |||
| Day Low | $105.39 | EPS | $-0.56 | |||
| Volume | 2,609 | |||||
